ABL BIO revenue for the last year amounted to 65.80 B KRW, the most of which — 65.55 B KRW — came from its highest performing source at the moment, Bio-Protein Recombinant Medicines, the year earlier bringing 67.30 B KRW. The greatest contribution to the revenue figure was made by United States — last year it brought ABL BIO 63.55 B KRW, and the year before that — 62.32 B KRW.